PUBLISHER: The Business Research Company | PRODUCT CODE: 2133805
PUBLISHER: The Business Research Company | PRODUCT CODE: 2133805
The machine learning (ML) in the pharmaceutical industry market refers to the use of artificial intelligence (AI) algorithms and techniques to improve various aspects of drug discovery, development, and manufacturing processes. Implementing ML solutions in the pharmaceutical industry requires adherence to regulatory requirements while addressing challenges associated with data quality, research limitations, and regulatory uncertainty.
The primary components of machine learning (ML) in the pharmaceutical industry include solutions and services. A solution refers to an application or system that leverages machine learning algorithms and techniques to address specific challenges or tasks within the pharmaceutical domain. Its deployments include cloud and on-premise, and it serves enterprises of different sizes, including small and medium enterprises (SMEs) and large enterprises.
Tariffs are influencing the machine learning in the pharmaceutical industry market by increasing the costs of imported advanced computational hardware, cloud infrastructure, and specialized laboratory equipment. Segments such as predictive analytics tools and clinical trial optimization solutions are particularly affected, especially in regions such as North America and Europe that depend on imported AI technologies. While these tariffs are raising operational costs and slowing adoption in some cases, they are also encouraging local manufacturing and sourcing of AI hardware, supporting regional innovation and the development of cost-efficient solutions.
The machine learning (ml) in the pharmaceutical industry market research report is one of a series of new reports from The Business Research Company that provides machine learning (ml) in the pharmaceutical industry market statistics, including machine learning (ml) in the pharmaceutical industry industry global market size, regional shares, competitors with a machine learning (ml) in the pharmaceutical industry market share, detailed machine learning (ml) in the pharmaceutical industry market segments, market trends and opportunities, and any further data you may need to thrive in the machine learning (ml) in the pharmaceutical industry industry. This machine learning (ml) in the pharmaceutical industry market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The machine learning (ml) in the pharmaceutical industry market size has grown exponentially in recent years. It will grow from $4.09 billion in 2025 to $5.55 billion in 2026 at a compound annual growth rate (CAGR) of 35.6%. The growth during the historic period can be attributed to increasing R&D investment in pharmaceuticals, growing adoption of AI and ML in drug discovery, rising prevalence of chronic diseases, advancements in computational biology, and increasing collaboration between pharmaceutical and technology companies.
The machine learning (ml) in the pharmaceutical industry market size is expected to see exponential growth in the next few years. It will grow to $18.86 billion in 2030 at a compound annual growth rate (CAGR) of 35.8%. The growth during the forecast period can be attributed to growing integration of AI in clinical trials, expansion of precision medicine, increasing use of real-world data analytics, advancements in cloud-based pharmaceutical platforms, and development of personalized therapeutics. Major trends during the forecast period include predictive drug discovery models, optimization of clinical trials, utilization of real-world evidence data, implementation of personalized medicine, and automation of regulatory compliance.
The increasing adoption of artificial intelligence (AI) is driving the growth of machine learning (ML) in the pharmaceutical industry. AI refers to computer software designed to replicate aspects of human cognition to perform complex tasks, including analysis, reasoning, and learning, while ML is a subset of AI that uses algorithms trained on data to develop models capable of performing complex tasks. AI and ML are increasingly being utilized in pharmaceutical technology and drug delivery design, providing faster solutions to complex challenges. These technologies have the potential to transform drug delivery processes, improve decision-making tools, and process large volumes of data to support more effective decision-making. For instance, in June 2023, according to Forbes, a US-based business magazine, approximately 432,000 organizations in the UK, or one in six, had adopted at least one AI technology. Further, at least one AI technology had been adopted by 68% of large businesses, 33% of medium-sized businesses, and 15% of small businesses. Therefore, the increasing adoption of artificial intelligence (AI) will drive the growth of machine learning (ML) in the pharmaceutical industry.
Major companies operating in the machine learning (ML) in the pharmaceutical industry market are focusing on developing user-friendly software platforms, such as drug discovery software, to enhance their drug discovery capabilities. Drug discovery software refers to a broad range of specialized tools and platforms used throughout the process of identifying and developing new pharmaceutical drugs. For instance, in December 2023, Merck & Co. Inc., a US-based pharmaceutical company, launched AIDDISON, a drug discovery software and the first software-as-a-service platform to integrate drug discovery and synthesis using generative AI, machine learning, and computer-aided drug design. The platform enables laboratories to identify potential drug candidates across a vast chemical space, virtually screen compounds from a universe of more than 60 billion chemical targets, and evaluate synthesis routes to support safer, more cost-effective, and higher-yield drug manufacturing.
In July 2023, BioNTech SE, a Germany-based biopharmaceutical company, acquired InstaDeep for $541 million. The acquisition is expected to reinforce BioNTech's leading position in AI-powered drug discovery, design, and development. InstaDeep is a UK-based technology company that provides AI solutions and machine learning services for the pharmaceutical industry.
Major companies operating in the machine learning (ml) in the pharmaceutical industry market are Amazon.com Inc., Alphabet Inc., Microsoft Corporation, Dell Technologies Inc., Hitachi Ltd., International Business Machines Corporation, Cisco Systems Inc., Oracle Corporation, Honeywell International Inc., Hewlett Packard Enterprise, NVIDIA Corporation, Thales SA, Atos SE, Hexagon AB, Palantir Technologies Inc., Alteryx Inc., Comet ML Inc., GAVS Technologies, NEC Corporation, Veritone Inc., H2O.ai Inc., Sparkcognition Inc., Akira AI, Deep Genomics Inc., Cloud Pharmaceuticals Inc., Atomwise Inc., Cyclica Inc., BioSymetrics Inc., Neptune Labs
North America was the largest region in the machine learning in the pharmaceutical industry market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the machine learning (ml) in the pharmaceutical industry market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the machine learning (ml) in the pharmaceutical industry market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The machine learning (ML) in the pharmaceutical industry market consists of revenues earned by entities by providing components of machine learning (ML) in the pharmaceutical industry market such as solutions and services. The market value includes the value of related goods sold by the service provider or included within the service offering. The machine learning (ML) in the pharmaceutical industry market also includes sales of central processing units (CPUs), random access memory, storage systems, and graphics processing units (GPUs). Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Machine Learning (ML) in The Pharmaceutical Industry Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses machine learning (ml) in the pharmaceutical industry market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for machine learning (ml) in the pharmaceutical industry ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The machine learning (ml) in the pharmaceutical industry market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.